TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Process: The condensation of 4,5,6,7-tetrahydrothieno(3,2-c)pyridine hydrochloride with 2-bromo-2-(2-chlorophenyl)acetic acid of step (i) is carried out in water under basic conditions and at room temperature, preferably at 22-27 degrees C. The 2-(2-chlorophenyl)-2-(6,7-dihydrothieno(3,2-c)pyridine-5(4H)-yl)acetic acid obtained from step (i) is obtained by adjusting the pH value of the reaction mass and isolating the precipitated material. The optical resolution process of step (ii) is carried out in ethanol media. The (S)- 2-(2-chlorophenyl)-2-(6,7-dihydrothieno(3,2-c)pyridine-5(4H)-yl)acetic acid L-di-O-benzoyl tartaric acid salt of step (ii) is obtained by fractional crystallization. The conversion of (S)-2-(2-chlorophenyl)-2-(6,7-dihydrothieno(3,2-c)pyridine-5(4H)-yl)acetic acid L-di-O-benzoyl tartaric acid salt of step (iii) is achieved through esterification. The esterification is performed by dissolving the (S)-2-(2-chlorophenyl)-2-(6,7-dihydrothieno(3,2-c)pyridine-5(4H)-yl)acetic acid in methanol and thionyl chloride is added to it. The esterification reaction is carried out under argon atmosphere. The clopidogrel obtained in step (iii) is converted into clopidogrel besylate by treating clopidogrel with benzene sulfonic acid. The clopidogrel besylate is recrystallized in a mixture of isopropanol and tert-butyl methyl ether. The de-salting process of step (iv) is carried out by extraction using ethyl acetate and water. The racemization process of step (iv) is performed in water under basic conditions and in a high pressure reactor. ACTIVITY - Cerebroprotective; Vasotropic; Anticoagulant; Thrombolytic.    MECHANISM OF ACTION - None given.    EXAMPLE - (S)-2-(2-Chlorophenyl)-2-(6,7-dihydrothieno(3,2-c)pyridin-5(4H)-yl)acetic acid L-di-O-benzoyl tartaric acid salt (100 g) was charged into a 3-neck 2l round-bottom flask. Then ethyl acetate (550 ml) and demineralized water (550 ml) were added into the reaction mixture. Hydrochloric acid (100 ml) was added slowly under stirring. The aqueous layer was collected and mixed with ethyl acetate (690 ml). Aqueous sodium hydroxide solution (94 ml) was added under stirring until pH becomes 3.5 to 4. The aqueous layer was back extracted with ethyl acetate (690 ml). The organic layers are combined and dehydrated over sodium sulfate anhydrous (40 g). The solid was filtered off under vacuum and the filtrate was evaporated to dryness. The residue was dissolved in methanol (170 ml) and the solvent was evaporated to dryness. The residue was dissolved in methanol (95 ml) and the solvent was evaporated again to dryness. The obtained residue was dissolved in methanol (500 ml) and argon atmosphere was applied. Thionyl chloride (45 ml) was added at 20-25 degrees C. The reaction mixture was heated at 55-60 degrees C for 8 hours under stirring. The reaction mixture was evaporated to dryness and worked up to give organic layer. The organic layer was dried over anhydrous sodium sulfate (30 g) and the solid was filtered and filtrate was evaporated. The residue was dissolved in isopropanol (30 ml) and the solvent was evaporated to dryness. Isopropanol (180 ml) was added to the residue. The reaction mixture was heated to 35-40 degrees C and then benzenesulfonic acid (22.5 g) was added and heated. Then tert-butyl methyl ether (40 ml) was added and the reaction mixture was worked up to give crude (S)-2-(2-chlorophenyl)-2-(6,7-dihydrothieno(3,2-c)pyridin-5(4H)-yl)acetic acid besylate. Crude clopidogrel besylate (100 g) was charged into a 1 l 3-neck round-bottom flask and isopropanol (300 ml) was added. The reaction mixture was heated to 55-60 degrees C and the reaction solution was filtered and reheated to 55-60 degrees C. Then tert-butyl methyl ether (100 ml) was added and the reaction mixture was worked up to obtain (S)-2-(2-chlorophenyl)-2-(6,7-dihydrothieno(3,2-c)pyridin-5(4H)-yl) acetic acid besylate.